United States: Another Prescription Drug Warnings Preemption Decision

Last Updated: July 1 2016
Article by Eric Alexander

Not that our readers are dying for a glimpse behind the curtain into the making of the sausage (and mixed metaphors) of the blog, but we do try to first figure out what decisions may be blogworthy before we start writing up the posts each week. We cannot say how blogworthiness relates to spongeworthiness, but we do know that the former involves asking a few questions, one of which is "is this just the same old same old?" In other words, even if the decision comes from a product liability case with a drug or device and addresses something that we think matters, we will not write about it if it adds nothing more than being another decision like we have seen many times before. Maybe it will be added to some cheat sheet or other compilation post, but it will not be worthy of its own post on this illustrious blog. (So illustrious are we that have noticed other blogs trying to rip off our name in the hopes that they will confuse search engines into directing traffic their way.)

When Levine came out with its misreading of the CBE regulation and novel "clear evidence" standard for impossibility preemption, we certainly did not think it would become so commonplace for prescription drug manufacturers—branded, in particular, although the liability of generics was not much of a concern then—to win warnings claims based on preemption. We are not yet there, but we can envisage a day where wins like in Seufert v. Merck Sharp & Dohme Corp., No. 13cv2928, 2016 WL 3369512 (S.D. Cal. May 11, 2016), just end up in our handy-dandy Levine cheat sheetFor now, Seufert is still blogworthy.

Here are the basic facts. Plaintiffs sued over allegedly inadequate (absent) warnings on a purported risk of pancreatic cancer with two anti-diabetes drugs—the same compound is in each, with one adding metformin—within a class of drugs called incretin mimetics or incretin-based therapies. There are a number of approved drugs in this class, including one with its active ingredient derived from Gila monster venom. The two at issue were approved in 2009 and 2010 and there has been some degree of attention by FDA to a proposed risk of pancreatic cancer since they came on the market. It is not clear if plaintiffs contended that there was pre-marketing evidence of a pancreatic cancer risk specific to these two drugs, but we assume they did not have much if anything. In 2009, FDA reviewed adverse event data for the class of drugs and concluded "a causal association . . . is indeterminate as this time." In 2013, FDA issued a "Drug Safety Communication" stating that it was analyzing the issue of pancreatitis and pancreatic cancer with the class of drugs, but that "it had not reached a new conclusion regarding whether incretin mimetics cause pancreatic cancer, and advised health care professionals to continue following the prescribing recommendations in the drug labeling"—which did not mention pancreatic cancer. Based on the plaintiffs' case numbers, it looks like this Communication started them suing.

In February 2014, FDA and the European Medicines took the fairly unusual step of publishing an article in the New England Journal of Medicine to report on the results of the FDA's analysis mentioned in the Communication and the EMA's own analysis.

Both agencies agree that a causal association between pancreatitis and pancreatic cancer as expressed recently in the scientific literature and media are inconsistent with the current data . . . . The FDA and EMA believe that the current knowledge is adequately reflected in the product information and labeling.

In March 2014, FDA denied a citizen petition to remove a particular drug in the class from the market based on the purported risk of pancreatic cancer and other things. (We checked and it was filed by—shocker—Public Citizen. One need not dig deeply to find the ties between that group and the lawyers who bring these cases.) The denial noted there was "no new evidence regarding the risk of pancreatic carcinoma in association with the use of [the drug] that would support any changes to the current approved labeling"—which did not discuss pancreatic cancer. Based on this history, the defendants moved to dismiss the warnings claims based on conflict preemption. The court denied it so that the cases could proceed to discovery before addressing the merits of preemption. Since then, FDA has approved other drugs in the class without any warnings about a risk of pancreatic cancer in their labels. Apparently, none of the manufacturers have asked to add such a warning to the label, so the FDA has never rejected such a request.

For those following along on preemption of prescription drug warnings claims, the battle lines for summary judgment were clearly drawn from these facts. For those really following, you might recall that we have posted previously on two decisions finding preemption with other drugs of this same class, including in a decision by the same judge With this background, the plaintiffs first advanced two arguments to try to avoid a detailed consideration of the regulatory record on the question of whether there was clear evidence that the FDA would have rejected the plaintiffs' proposed labeling change. They claimed that the FDA had to have rejected a proposed labeling change from the/a manufacturer, but Levine did not say that and cases had found preemption without such a rejection. They also claimed that only FDA's consideration of a proposed warning counts as evidence, not actions relating to whether there is a risk. There is some irony to this latter argument as plaintiffs tend to be loath to specify the form and content of the warning that would have been adequate, even while arguing about the actual label and whether it should and could have been changed. In any event, the court patiently rejected what was a pretty silly argument given the facts of this case. Again, nothing in Levine—including the regulatory history of the drug and warning at issue—suggested such a limitation. More importantly, these plaintiffs argued that a risk not in the label needed to be added, which the court characterized as plaintiffs seeking a new warning "that incretin mimetics cause or increased the risk of pancreatic cancer." To add such a warning, in any part of the label, requires an assessment of whether FDA believes such a risk is supported by the data. As set out in our discussion of the facts, "[t]he FDA's review therefore directly corresponds to the claims at issue in this litigation," even the review was not occasioned by a proposed labeling change.

We think this is right, but a broader understanding of FDA's regulation of drugs would show that consideration of risk and labeling implication are commonly connected, which is evidenced by the references to labeling in the Communications, NEJM publication, citizen petition denial, and at least the vast majority of approval letters for NDAs and NDA supplements and even internal memoranda evaluating periodic submissions. It is said that FDA approves labels more than it approves drugs. Anyone who has spent much time reviewing submissions to FDA and documents generated by FDA about those submissions and analyses that FDA does on its own should come to the realization that labeling is the linchpin. The same conclusion can be reached by reviewing the chunk of 21 CFR focused on prescription drugs. Approval letters, for instance, say the drug is approved because of proof that it is "safe and effective for use as recommended in the label" (give or take on the language) and post-marketing submissions relating to risk and the review of those are always tied to whether the current label says what it should about the risk. FDA evaluations of risk information, whether from studies, collections of spontaneous reports, or some more systematic review of spontaneous reports, always involves a question of whether labeling (draft or approved) needs to be changed in some fashion. A statement in an FDA review memorandum that "no action is recommended" or "no changes to labeling are recommended" really means the reviewer, in her official capacity, has concluded that the current label appropriately describes the current evidence of the risk of each adverse event discussed in what was reviewed, including where the label does not mention the event at all. The FDA reviewers are not writing their memoranda with an eye towards how some judge will interpret their preemptive effect, so a greater understanding of the overall scheme will have to suffice.

Returning from our segue, we note the court's thoroughness in explaining that the evidence showed "that the FDA would have rejected a pancreatic cancer labeling change" and the plaintiffs' arguments to the contrary were unavailing. "The FDA's repeated conclusion that scientific data did not support warning of pancreatic cancer risk coupled with the FDA's statement that product labeling was adequate amounts to clear evidence that the FDA would have rejected a pancreatic cancer labeling change." With regard to the Levine argument that a CBE was available to make a temporary labeling change, "Defendants did not have a duty to submit a pancreatic cancer warning to the FDA because the risk of pancreatic cancer was never readily apparent from available data." Not only would FDA have rejected a CBE the same way it would have rejected a prior approval submission, but public policy runs contrary to requiring requested labeling changes without sufficient scientific support:

A rule to the contrary would encourage prophylactic labeling changes by manufacturers, which, in turn, could inundate the FDA with labeling submissions. This could lead to overwarning consumers and deterring potentially beneficial use of prescription drug,

Consistent with the "well-settled maxim of jurisprudence that the law does not require idle acts, without sufficient data to justify a labeling request, "Defendants did not have to submit a pancreatic cancer labeling change to establish conflict preemption." In short, the evidence was about as clear as one could envision in the absence of a denial of a request to change the label in the same way plaintiffs contend was required.

Plaintiffs raised two additional arguments. First, because FDA did not consider its statements "final" while additional risk evidence was being accumulated, particularly clinical studies, plaintiffs claimed a rejection of a proposed labeling change was not clear. The court saw that risk evidence on marketed drugs—or classes of drugs—so waiting for a truly "final" statement would allow the court to do its job. As with Daubert rulings, the implications of the present science can be tested at an appropriate time after the plaintiffs chose to bring their cases. Second, plaintiff s contended that FDA had been inconsistent with regard to allowing pancreatitis in labeling while saying a causal relationship had not been established. This was a red herring because FDA described the level of proof of association differently for the different conditions.

Plaintiffs also asked to extend discovery to "obtain information about the FDA's actions and potential new safety information in Defendants' possession." We will not belabor it, but no last minute charge from the Knights of the Vale was coming to change the result here. It also seems that, although the court did not rely on any of it in finding conflict preemption, that on-going studies of the particular drugs at issue showed no increased risk of pancreatic cancer. That should provide some comfort that the timing of the decision did not work against plaintiffs. Speaking of timing, we wonder why the publicly available information back in the spring of 2014—when the motion to dismiss was denied—would not have been enough to reach the same result. It does not look like discovery—which we presume was costly for both sides, but more costly for defendants—turned up anything that was critical to the decision. It will probably be a while until we start compiling cases with branded prescription drug warnings claims preempted before defendants are subject to any discovery.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.